Literature DB >> 32762449

Tuberculosis and beta-lactam antibiotics.

Mehmet Akif Gun1, Bulent Bozdogan2, Ahmet Yilmaz Coban3,4.   

Abstract

Tuberculosis (TB) is one of the oldest health problems in the world and it remains unresolved. Multidrug-resistant-TB and extensively resistant-TB are a serious problem for control programs. The evaluation of available antibiotics has gained importance in recent years for the treatment of resistant TB. Beta-lactam antibiotics inhibit cell wall biosynthesis in the bacteria; the presence of beta-lactamase enzyme in TB bacilli raises the question of whether this group of antibiotics can be used in treatment. As a result, it has been reported that the combination of beta-lactam antibiotics with beta-lactamase is effective against Mycobacterium tuberculosis both in vitro and in vivo. The aim of this article is to review and discuss up-to-date knowledge and future perspective on beta-lactam antibiotics and TB.

Entities:  

Keywords:  MDR; XDR; tuberculosis; β-lactams

Year:  2020        PMID: 32762449     DOI: 10.2217/fmb-2019-0318

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  1 in total

1.  Mass spectrometry reveals potential of β-lactams as SARS-CoV-2 Mpro inhibitors.

Authors:  Tika R Malla; Anthony Tumber; Tobias John; Lennart Brewitz; Claire Strain-Damerell; C David Owen; Petra Lukacik; H T Henry Chan; Pratheesh Maheswaran; Eidarus Salah; Fernanda Duarte; Haitao Yang; Zihe Rao; Martin A Walsh; Christopher J Schofield
Journal:  Chem Commun (Camb)       Date:  2021-02-15       Impact factor: 6.222

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.